BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN)
Clinical trials for BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN) explained in plain language.
Never miss a new study
Get alerted when new BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN) trials appear
Sign up with your email to follow new studies for BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take aim at stubborn blood cancers in early trial
Disease control Recruiting nowThis early-phase trial tests a personalized cell therapy called CART123 for adults with certain blood cancers (like acute myeloid leukemia) that have not responded to standard treatments. Each patient's own immune cells are collected, modified to target a protein called CD123 on …
Matched conditions: BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN)
Phase: EARLY_PHASE1 • Sponsor: Institute of Hematology and Blood Transfusion, Czech Republic • Aim: Disease control
Last updated May 02, 2026 19:44 UTC
-
Rare cancer mystery: global registry launches to crack BPDCN code
Knowledge-focused Recruiting nowThis study creates a worldwide registry for people diagnosed with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), a very rare blood cancer. Researchers will collect information on patient symptoms, treatments, and outcomes to better understand the disease and find the best …
Matched conditions: BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN)
Sponsor: Immune Oncology Research Institute • Aim: Knowledge-focused
Last updated Apr 30, 2026 15:52 UTC